Evidence map›Paper›PMID 33794353›Full record

Trial reportContemporary clinical trials2021

Optimizing drug inventory management with a web-based information system: The TBTC Study 31/ACTG A5349 experience.

Nigel A Scott, Kara K Lee, Claire Sadowski, Ekaterina V Kurbatova, Stefan V Goldberg, Pheona Nsubuga, Rene Kitshoff, Colleen Whitelaw, Hanh Nguyen Thuy, Kumar Batra and 9 more

Registry-linked trialAbstract readClinical Trial
In one paragraph

Trial report in Contemporary clinical trials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02410772 (Rifapentine-containing Treatment Shortening Regimens for Pulmonary Tuberculosis), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02410772 phase3completednot on this map

Rifapentine-containing Treatment Shortening Regimens for Pulmonary Tuberculosis: A Randomized, Open-label, Controlled Phase 3 Clinical Trial. TBTC Study 31, ACTG Study A5349

TypeinterventionalSponsorCenters for Disease Control and PreventionRan2016 to 2021Enrolled2,516ConditionsTuberculosisArmsrifapentine, rifapentine and moxifloxacin, control
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Nigel A ScottU.S. Centers for Disease Control & Prevention, Atlanta, GA, USA. Electronic address: NScott@cdc.gov.
Kara K LeeU.S. Centers for Disease Control & Prevention, Atlanta, GA, USA.
Claire SadowskiU.S. Centers for Disease Control & Prevention, Atlanta, GA, USA; Oak Ridge Institute for Science and Education, Oak Ridge, TN, USA.
Ekaterina V KurbatovaU.S. Centers for Disease Control & Prevention, Atlanta, GA, USA.
Stefan V GoldbergU.S. Centers for Disease Control & Prevention, Atlanta, GA, USA.
Pheona NsubugaUganda - Case Western Reserve University Research Collaboration, Kampala, Uganda.
Rene KitshoffTASK Applied Science CRS, Stellenbosch, South Africa.
Colleen WhitelawUniversity of Cape Town Lung Institute (Pty) Ltd (UCTLI), Centre for Tuberculosis Research Innovation (CTBRI), Cape Town, South Africa.
Hanh Nguyen ThuyVietnam National Tuberculosis Program/University of California San Francisco Research Collaboration, Hanoi, Viet Nam.
Kumar BatraPeraton Corporation, Herndon, VA, USA.
Cynthia Allen-BligePeraton Corporation, Herndon, VA, USA.
Howard DavisPeraton Corporation, Herndon, VA, USA.
Jay KimPeraton Corporation, Herndon, VA, USA.
Mimi PhanNorthrop Grumman Corporation, San Diego, CA, USA.
Pamela FedrickPeraton Corporation, Herndon, VA, USA.
Kuo Wei ChiuNorthrop Grumman Corporation, San Diego, CA, USA.
Charles M HeiligU.S. Centers for Disease Control & Prevention, Atlanta, GA, USA.
Erin SizemoreU.S. Centers for Disease Control & Prevention, Atlanta, GA, USA.
AIDS Clinical Trials Group and The Tuberculosis Trials Consortium

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
Validation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8M
Intramural CDC HHS CC999999NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI106701
6 · The paper itself

Abstract

introductionEfficient management of study drug inventory shipments is critical to keep research sites enrolling into multisite clinical treatment trials. A standard manual drug-management process used by the Tuberculosis Trials Consortium (TBTC), did not accommodate import permit approval timelines, shipment transit-times and time-zone differences. We compared a new web-based solution with the manual process, during an international 34-site clinical trial conducted by the TBTC and the AIDS Clinical Trials Group (ACTG); TBTC Study 31/ACTG A5349. MATERIAL AND

methodsWe developed and implemented a technological solution by integrating logistical and regulatory requirements for drug importation with statistical simulations that estimated stock-out times in an online Drug Management Module (DMM). We measured the average shipment-related drug stock-outs and time to drug availability, to assess the efficiency of the DMM compared to the manual approach.

resultsAn Interrupted Time-Series (ITS) analysis showed a 15.4% [p-value = 0.03; 95% C.I. (-28.8%, -2.0%)] reduction in average shipment-related study drug stock-out after DMM implementation. The DMM streamlined the restocking process at study sites, reducing median transit-time for sites associated with a depot by 2 days [95% C.I. (-3.0, -1.0)]. Under the DMM, study drugs were available for treatment assignment on the day received, compared to one day after receipt under the manual process. DISCUSSION: The DMM provided TBTC's Data and Coordinating Center and site staff with more efficient procedures to manage and consistently maintain study drug inventory at enrolling sites. This DMM framework can improve efficiency in future multicenter clinical trials.

trial registrationThis trial was registered with ClinicalTrials.gov (Identifier: NCT02410772) on April 8, 2015.

Indexed as

Pharmaceutical PreparationsTuberculosisHumansInformation SystemsInternetResearch DesignPharmaceutical PreparationsInterrupted time-series analysisStatistical simulationsStudy drug inventory managementStudy drug stock-outTrial pharmaceuticalsWeb-based system

Identifiers

PMID33794353
PMCPMC9466280

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.